Tscherne Alina, Meyer Zu Natrup Christian, Kalodimou Georgia, Volz Asisa
Division of Virology, Department of Veterinary Science, LMU Munich, Oberschleißheim, Germany.
Institute of Virology, University of Veterinary Medicine Hannover, Hannover, Germany.
Methods Mol Biol. 2025;2860:297-340. doi: 10.1007/978-1-0716-4160-6_20.
Modified Vaccinia Virus Ankara (MVA) is a highly attenuated and replication-deficient vaccinia virus developed through serial passages in chicken embryo fibroblasts (CEF). MVA is increasingly used in biomedicine for vaccine development in preclinical and clinical studies in humans. Major benefits of MVA include a well-established record in clinical safety, long-standing experience in genetic engineering of the virus, a large data set demonstrating efficacy in preclinical models with the capacity to induce both protective antigen-specific antibody and cellular immune responses, and the availability of virus production under Good Manufacturing Practice (GMP) suitable for industrial scale amplification. In this chapter, we describe established state-of-the-art protocols for generating, amplifying, and purifying recombinant MVA viruses, including possible vector viruses for further investigations as well as clinical evaluation.
安卡拉痘苗病毒（MVA）是一种高度减毒且复制缺陷的痘苗病毒，通过在鸡胚成纤维细胞（CEF）中连续传代培养而成。MVA在生物医学领域越来越多地用于人类临床前和临床研究中的疫苗开发。MVA的主要优势包括临床安全性方面有充分的记录、在病毒基因工程方面有长期经验、大量数据集表明其在临床前模型中具有诱导保护性抗原特异性抗体和细胞免疫反应的功效，以及具备符合药品生产质量管理规范（GMP）的病毒生产条件，适合进行工业规模扩增。在本章中，我们描述了用于产生、扩增和纯化重组MVA病毒的成熟的先进方案，包括可用于进一步研究及临床评估的可能载体病毒。
